Anebulo Pharmaceuticals (Anebulo Pharmaceuticals) Price-to-Tangible-Book : 11.80 (As of May. 05, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Anebulo Pharmaceuticals Price-to-Tangible-Book?

As of today (2024-05-05), Anebulo Pharmaceuticals's share price is $2.95. Anebulo Pharmaceuticals's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $0.25. Hence, Anebulo Pharmaceuticals's Price to Tangible Book Ratio of today is 11.80.

The historical rank and industry rank for Anebulo Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

ANEB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.75 Med: 7.59 Max: 11.8
Current: 11.8

During the past 4 years, Anebulo Pharmaceuticals's highest Price to Tangible Book Ratio was 11.80. The lowest was 3.75. And the median was 7.59.

ANEB's Price-to-Tangible-Book is ranked worse than
90.67% of 1222 companies
in the Biotechnology industry
Industry Median: 2.715 vs ANEB: 11.80

A closely related ratio is called PB Ratio. As of today, Anebulo Pharmaceuticals's share price is $2.95. Anebulo Pharmaceuticals's Book Value per Sharefor the quarter that ended in Dec. 2023 was $0.25. Hence, Anebulo Pharmaceuticals's P/B Ratio of today is 11.80.

Anebulo Pharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for Anebulo Pharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anebulo Pharmaceuticals Price-to-Tangible-Book Chart

Anebulo Pharmaceuticals Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Price-to-Tangible-Book

7.44

8.06

5.68

Anebulo Pharmaceuticals Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial									4.01	5.74	5.68	9.40	9.68

Competitive Comparison of Anebulo Pharmaceuticals's Price-to-Tangible-Book

For the Biotechnology subindustry, Anebulo Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anebulo Pharmaceuticals's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anebulo Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Anebulo Pharmaceuticals's Price-to-Tangible-Book falls into.

Anebulo Pharmaceuticals Price-to-Tangible-Book Calculation

Anebulo Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	2.95	/	0.25
	=	11.80

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Anebulo Pharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Anebulo Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Anebulo Pharmaceuticals (Anebulo Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anebulo Pharmaceuticals Inc (NAS:ANEB) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

214:Germany

Address

1017 Ranch Road 620 South, Suite 107, Lakeway, TX, USA, 78734

Website

https://www.anebulo.com

Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.

Executives

Bimal R. Shah	director	C/O SPECTRUM PHARMACEUTICALS, 11500 SOUTH EASTER AVENUE, SUITE 240, HENDERSON NV 89052
Richard Anthony Cunningham,	director, officer: Chief Executive Officer	ONE KENDALL SQUARE, BUILDING 200 SUITE 2, CAMBRIDGE MA 02139
Dan George	officer: Chief Financial Officer	1412 62ND STREET, EMERYVILLE CA 94608
Sandra A. Gardiner	officer: Acting Chief Financial Officer	CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Kenneth C Cundy	officer: Chief Scientific Officer	1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Nathaniel Calloway	director	C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Simon Allen	director, officer: Chief Executive Officer	C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Aron R. English	director, 10 percent owner	1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Kenneth Lin	director	PO BOX 1005, LOS ALTOS CA 94022
Karah Herdman Parschauer	director	60 LEVERONI COURT, NOVATO CA 94949
22nw Fund, Lp	10 percent owner	1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Joseph F. Lawler	director, 10 percent owner	2110 RANCH ROAD 620 S, #341732, LAKEWAY TX 78734
Areta Kupchyk	director	C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Jason Aryeh	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
22nw, Lp	10 percent owner, other: See Explanation of Response	590 1ST AVE S, UNIT C1, SEATTLE WA 98104